Aft Forsyth & Sober’s Biogen BIIB Stock Holding History

Aft Forsyth & Sober’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-125	Closed	-$33K	–	34
2020 Q2	$33K	Buy	+125	New	+$37.6K	0.23%	56

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Aft Forsyth & Sober's BIIB Position: Q3 2020 in Review

Aft Forsyth & Sober sold out of Biogen (BIIB) in Q3 2020, closing a stake of 125 shares — an estimated $33K sold.

Aft Forsyth & Sober first reported a position in BIIB in Q2 2020 and held it in 1 quarter. The position peaked at $33K in Q2 2020. 1,051 funds tracked by Wall St. Rank hold BIIB as of Q3 2020.

Aft Forsyth & Sober reported no remaining Biogen position as of Q3 2020 after selling out during the quarter.
Aft Forsyth & Sober sold 125 Biogen shares in Q3 2020, an estimated $33K.
Aft Forsyth & Sober first reported a position in Biogen in Q2 2020 and held it in 1 quarter.
Aft Forsyth & Sober's Biogen position peaked at $33K in Q2 2020.
1,051 funds tracked by Wall St. Rank held Biogen as of Q3 2020.

Based on Aft Forsyth & Sober's 13F filing for Q3 2020, filed 14 Oct 2020.